Edaravone

Treatment for Motor neuron disease

Typical Dosage: 60 mg IV infusion daily for 14 days, followed by 14-day break; subsequent cycles 10 of 14 days, 14-day break (Oral suspension also available)

Effectiveness

55%

Safety Score

65%

Clinical Trials

Participants

600

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Treatment Details

Dosage Range

60 mg IV infusion daily for 14 days, followed by 14-day break; subsequent cycles 10 of 14 days, 14-day break (Oral suspension also available)

Time to Effect

3-6 months

Treatment Duration

Lifetime (cycles)

Evidence Quality

HIGH

Number Needed to Treat (NNT)

7(Treat 7 patients to see 1 additional successful outcome)

Number Needed to Harm (NNH)

10(Treat 10 patients to see 1 additional serious adverse event)

Confidence Score

85%confidence in effectiveness data

Health Economics

Annual Cost of Care

Drug Cost:$165,000

Monitoring:$7,500

Side Effect Mgmt:$500

Total Annual:$173,000

Cost-Effectiveness Analysis

Cost-Effectiveness Rating

POOR

ICER

$500,000/QALY

QALYs Gained

0.07

Comparison vs Riluzole + Best Supportive Care

Cost Difference

+$170,500/year

More expensive

QALY Difference

+0.07 QALYs

Better outcomes

Dominance

No dominance

Edaravone Outcomes

for Motor neuron disease

Efficacy Outcomes

Overall Effectiveness

+55%

Common Side Effects

Contusion

+9.6%

Gait disturbance

+8.4%

Headache

+7.2%

Infusion site reaction

+7%

Sources:

neurores.org

nih.gov

clinicalcasereportsint.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT

Active Clinical Trials

3 active trials recruiting for Edaravone in Motor neuron disease